Physician profile
Stephen G Werth
NPI 1093762734
$2,627.68
in general payments reported to CMS, 2019-2025
23 companies · $387 in 2025
The $387 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $292 · 2020: $231 · 2021: $299 · 2022: $534 · 2023: $470 · 2024: $414 · 2025: $387.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,077 · Education: $195.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,076.53 |
| Education | $194.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $430.43 | 2019-2025 | Rinvoq, Skyrizi |
| Leo Pharma INC. | $228.12 | 2021-2025 | Adbry |
| Janssen Biotech, INC. | $223.75 | 2019-2023 | Tremfya |
| Incyte Corporation | $175.14 | 2021-2025 | Opzelura |
| Lilly USA, LLC | $166.68 | 2019-2025 | Ebglyss |
| Genentech USA, INC. | $155.57 | 2019-2023 | Xolair |
| Sun Pharmaceutical Industries INC. | $153.33 | 2020-2024 | |
| Novartis Pharmaceuticals Corporation | $139.59 | 2019-2025 | |
| Genzyme Corporation | $129.81 | 2020-2025 | |
| Sandoz INC. | $109.51 | 2023-2025 | Hyrimoz |
| Pfizer INC. | $108.53 | 2022-2024 | |
| Galderma Laboratories, L.P. | $104.46 | 2020-2025 | Nemluvio, Aklief |
| E.R. Squibb & Sons, L.L.C. | $93.66 | 2022-2025 | Sotyktu |
| Arcutis Biotherapeutics, INC. | $79.80 | 2024-2025 | Zoryve |
| Dermavant Sciences, INC. | $59.89 | 2023-2024 | Vtama |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $56.44 | 2019-2023 | Bimzelx |
| Regeneron Healthcare Solutions, INC. | $55.84 | 2024-2025 | Dupixent, Libtayo |
| Merz North America, INC. | $42.65 | 2019-2021 | |
| Dermira, INC. | $26.56 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.07 | 2023 | Spevigo |
| Mission Pharmacal Company | $22.85 | 2022 | |
| Botanix Sb INC | $22.22 | 2025 | Sofdra |
| Celgene Corporation | $16.78 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Werth listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.